Scilex Expands Global Rights to Gloperba®, Enhancing Gout Treatment Accessibility

Scilex Holding Company has announced an amendment to its license agreement with Romeg Therapeutics, granting Scilex exclusive ex-US commercialization rights to Gloperba®. This oral gout treatment, already licensed for US distribution, addresses the needs of patients who struggle with swallowing pills, offering adjustable dosing options that improve convenience and disease management, particularly for those with renal or hepatic impairment.

Gout, a rising global concern affecting up to 6.8% of certain populations, remains poorly managed, with fewer than half of patients receiving effective urate-lowering therapies. “Expanding Gloperba®'s availability globally is a critical step in improving treatment accessibility and adherence,” stated a Scilex representative. By broadening its reach, Scilex aims to address unmet needs in gout management, targeting improved outcomes for patients worldwide.